Primary Partners

Benefits of Early Intervention and Diagnosis of Congestive Heart Failure

Congestive heart failure continues to result in extensive hospitalizations in the United States, with estimated costs of $53 billion in 2030.

Overcoming difficulties in early diagnosis is essential in addressing this epidemic, especially due to the abundance of asymptomatic disease progression. Traditional physical examination findings typically lack the sensitivity and specificity for HF with reduced EF. This is secondary to the pathophysiology of chronic systolic heart failure with left ventricular and left atrial remodeling, which masks classically taught symptoms such as nocturnal dyspnea and exertional shortness of breath.

Attention to medical history that reveals changes in shortness of breath or sleep patterns serve as opportunities for early intervention. Biomarkers such as Brain Natriuretic Peptide (BNP) directly indicate myocardial structural changes and justify coordination with a cardiovascular specialist, where echocardiograms can effectively reveal this underlying condition.
When echocardiogram findings are under the management of specialized cardiac physicians, treatment can be drastically enhanced by the significant pharmacological advancements in CHF-related targets. In this setting, patients benefit from the addition of ARNIs, SGLT2 inhibitors, Verquvo and Ivabradine to traditional β-blocker, ACE inhibitor, ARB, aldosterone antagonist, and vasodilator regimens.

Neel R Patel, M.D. FACC
Preventative Cardiologist
Central Florida Heart Care